755 related articles for article (PubMed ID: 22589450)
1. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
Ganetsky A; Bhatt V
Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
Pavel ME; Wiedenmann B
Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
[TBL] [Abstract][Full Text] [Related]
3. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
4. Medical treatment of neuroendocrine tumours.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
[TBL] [Abstract][Full Text] [Related]
5. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
6. Advances in the systemic treatment of pancreatic neuroendocrine tumors.
Yalcin S
Cancer Treat Rev; 2011 Apr; 37(2):127-32. PubMed ID: 20705397
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract][Full Text] [Related]
8. [Neuroendocrine tumors: the age of targeted therapies].
Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
[TBL] [Abstract][Full Text] [Related]
9. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Faivre S; Sablin MP; Dreyer C; Raymond E
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
[TBL] [Abstract][Full Text] [Related]
10. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine tumors of the pancreas.
Milan SA; Yeo CJ
Curr Opin Oncol; 2012 Jan; 24(1):46-55. PubMed ID: 22080942
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic therapy of gastroenteropancreatic (GEP) tumors.
Syrigos KN; Sitara D; Georgiou E; Harrington KJ
Anticancer Res; 2002; 22(2B):1311-4. PubMed ID: 12168943
[TBL] [Abstract][Full Text] [Related]
14. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
15. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
Weber M
Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):12-7. PubMed ID: 25768104
[No Abstract] [Full Text] [Related]
16. Emerging therapies for advanced gastroenteropancreatic neuroendocrine tumors.
Gupta S; Engstrom PF; Cohen SJ
Clin Colorectal Cancer; 2011 Dec; 10(4):298-309. PubMed ID: 21813338
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogs for the treatment of neuroendocrine tumors.
Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
Massironi S; Conte D; Rossi RE
Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
20. Current medical treatment of pancreatic neuroendocrine tumors.
Yalcin S; Oyan B; Bayraktar Y
Hepatogastroenterology; 2007; 54(73):278-84. PubMed ID: 17419276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
